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18F-ﬂuorodeoxyglucose positron emission tomography (FDG-PET) plays an increasingly important role in the prognostication,
diagnosis,andmanagementofthyroid carcinoma.Forpatientsdiagnosedwithprimaryorpersistent/recurrent thyroid carcinoma,
a ﬁnding of FDG-PET positivity implies a more aggressive tumor biology and a distinct mutational proﬁle, both of which carry
prognostic signiﬁcance. Therefore, FDG-PET positivity may be a useful potential risk factor for preoperative risk stratiﬁcation in
primary thyroid carcinoma. This information may help in the planning of subsequent treatment strategy such as the extent of
thyroidectomy, prophylactic central neck dissection, and radioiodine ablation. FDG-PET scan has also been found to be a useful
adjunct in characterizing indeterminate thyroid nodules on ﬁne needle aspiration cytology. However, larger-sized prospective
studies are required to validate this ﬁnding. FDG-PET or FDG-PET/CT scan has become the imaging of choice in patients with a
negativewhole-body radioiodinescan,butwithanabnormallyraisedthyroglobulinlevelaftertotalthyroidectomyandradioiodine
ablation.
1.Introduction
18F-ﬂuoro-2-deoxy-D-glucose-positron emission tomogra-
phy (FDG-PET) scan is increasingly being used not only in
oncologybutalsoinsomenononcologicalspecialties, suchas
neurology, cardiology, and infectious diseases [1]. The fun-
damentalprincipleofFDG-PETscanisthatthenuclide,18F-
FDG has two parts, namely, the vector part (i.e., 2-deoxy-D-
glucose) and the positron emitting nuclide part (i.e., 18F),
and when it gets preferentially taken up by rapidly dividing
cells (i.e., malignant cells), it gets “trapped” within the cells
and emits positron radiation which is then detected by the
scintigraphy [2]. This is called metabolic trapping and this
forms the basis for FDG-PET scanning. In oncology, FDG-
PET has many important clinical applications including
initial cancer staging as well as monitoring tumor response
to anticancer therapy in lung, colon, lymphoma, melanoma,
esophageal cancer, and head and neck and breast cancer [3].
In neurology and cardiology, FDG-PET is a useful tool for
localization of epileptogenic zones inside the brain and is a
“goldstandard” toolforthe detectionofmyocardial viability,
respectively [4, 5].
Since the ﬁrst observation of FDG uptake in metastatic
th yr oidcancerover20y earsago[6],there havebeengrowing
interests in evaluating the role of FDG-PET scanning in the
management of thyroid neoplasms [7]. Also with an in-
creased number ofFDG-PETscansnowbeing performed, an
increasing number of incidental thyroid lesions (or the so-
called thyroid incidentalomas) have been found and this
itself poses a diagnostic challenge to clinicians. Given that
FDG-PET imaging could provide potentially relevant infor-
mation on tumor biology and the scan results may enable
to prognostically stratify thyroid carcinoma patients, the
authorbelievesthatitwouldbebothtimelyandimportantto
examine the prognostic signiﬁcance of FDG-PET positivity
in thyroid carcinoma and the role of FDG-PET in diagnosis2 Journal of Thyroid Research
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Figure 1: A 70-year-old lady underwent 18F-FDG PET for staging
of a rectal carcinoma. A focal right thyroid hypermetabolic uptake
(with a SUVmax of 5.9) was detected. This was later conﬁrmed as
papillary thyroid carcinoma (PTC) on cytology. A total thyroidec-
tomy was performed revealing a 1.3cm tall cell variant of PTC with
central compartment lymph nodes metastases (pT1N1a).
and management of thyroid carcinoma by a review of the
current literature.
2.PrognosticSigniﬁcance of
FDG-PET Positivityor FDGAvidityin
Thyroid Carcinoma
It has been well recognized that thyroid carcinoma metas-
tases which are shown up on FDG-PET scan do not take
up radioactive iodine (RAI) [7]. In fact, it was noted that
therewasareciprocalor“ﬂip-ﬂop”relationship betweenRAI
and FDG uptake [6]. Numerous reports have conﬁrmed this
important relationship [8]. At the same time, it was noted
that those metastases which did not take up RAI were gen-
erally less diﬀerentiated on histology and behaved clinically
more aggressively. Therefore, FDG-PET positivity in thyroid
carcinoma could imply clinically more aggressive tumors
and poorer overall prognosis. However, before discussing
the implications of FDG positivity in thyroid carcinoma, it
should be realized that there are fundamental diﬀerences in
the management of FDG-PET positivity between primary
and persistent/recurrent thyroid carcinoma. As a result, the
following discussion was subdivided into primary and per-
sistent/recurrent thyroid carcinoma.
3.PrognosticSigniﬁcance ofFDG-PET
Positivityin PrimaryThyroid Carcinoma
Unlike persistent/recurrent carcinoma, the number of stud-
ies examining the relationship between FDG-PET positivity
and tumor behavior or prognosis for primary thyroid car-
cinoma remained relatively few. As the role of FDG-PET in
preoperative thyroid carcinoma staging remains undeﬁned,
the majority of these primary thyroid carcinomas exhibiting
FDG-PET positivity are incidentally found cancers or inci-
dentalomas(seeFigure1).Reasonsforthelackofenthusiasm
for FDG-PET as a staging tool include that FDG-PET scan
remains arelativelyexpensive preoperativeimaging modality
when compared to ultrasound (USG) which is the recom-
mended imaging modality before surgery, and relative to the
other imaging modalities, FDG-PET does not seem to pro-
vide any additional staging information (such as the statusof
the cervical lymphnodes) to an extent of altering the surgical
management [9]. As a result, FDG-PET scan has not been
routinely advocated as a preoperative staging tool, although
theremightbearoleinselected,moreaggressive pathologies,
such as Hurthle cell or anaplastic thyroid carcinoma [10–
12]. Nevertheless, one of the ﬁrst studies examining the rela-
tionship between tumor behavior and FDG-PET positivity
in primary thyroid carcinoma was reported by Jeong et al.
[13]. In this study, they reported 44 consecutive patients
with papillary thyroid microcarcinoma (PTMC) conﬁrmed
by USG and ﬁne needle aspiration cytology (FNAC) who
subsequently underwent FDG-PET scans before surgery.
The clinicopathological characteristics of these 44 PTMC
were correlated with the activity of the FDG-PET scan or
FDG standardized uptakes values (SUVs). Although there
was a strong correlation between SUVs and extrathyroidal
extension of PTMC in the univariate analysis, the study did
not ﬁnd any association between the degree of SUV and
extrathyroidal extension or other aggressive tumor features
in the multivariate analysis [13]. Only age > 45 and tumor
site turned out to be the two signiﬁcant factors for determin-
ing extrathyroidal extension in primary PTMC [13]. SUVs
were correlated with tumor size, butthis was not unexpected
because there is the partial volume eﬀect between small-
and large-sized lesions. Therefore, based on this initial study,
FDG-PET positivity was not associated with more aggressive
t u m o rb e h a v i o ro rw o r s et u m o rc h a r a c t e r i s t i c s[ 13]. How-
ever, a more recent study found that for PTMCs which were
FDG nonavid, they were not only signiﬁcantly smaller sized
tumors but also less frequent perithyroidal tumor invasion
and lymphovascular invasion when compared to the PTMCs
which were FDG avid [14]. This implies that FDG-PET
positivity might be associated with a more aggressive tumor
behavior in primary thyroid carcinoma [14]. However, since
tumor size is an important factor for FDG-PET positivity as
itrelatestothepartial volumeeﬀect,itwouldbemoreappro-
priate to adjust for tumor size in these clinicopathological
studies.Yunetal.reportedtheirretrospective studyinvolving
87 patients with a unifocal PTMC who underwent preoper-
ative FDG-PET before total thyroidectomy and central neck
dissection [15].TheydeﬁnedpositiveFDGuptakeinPTMCs
as a discernible focal FDG uptake whereas negative FDG as
no discernible FDG uptake. All scans were assessed by two
experiencednuclearmedicinespecialistsblindedforpatients’
clinicaland pathologicalvariables. In theirmultivariate anal-
yses,amongotherfactors suchasgender,age,andtumorsize,
FDG-PET positivity was the only signiﬁcant factor which
strongly correlatedwith extrathyroidal extension (OR =5.95;
95% CI: 2.13–16.6) and central lymph node metastases in
primary PTMC [15]. This result indicates that visual FDG-
PET positivity in PTMCs is a potential risk factor which
could be useful in preoperative risk stratiﬁcation. One of the
potential clinical applications would be to use the preopera-
tiveﬁnding ofFDG-PETpositivity toselect patientsformore
extensive thyroid resection (i.e., hemithyroidectomy versusJournal of Thyroid Research 3
total thyroidectomy in PTMC) or for prophylactic central
neck dissection at the time of total thyroidectomy as it is
currently only indicated for high-risk tumors [10]. Our pre-
vious studies examining the behavior of FDG-avid primary
thyroid carcinoma (mostly incidental thyroid carcinoma)
also suggested that these tumors are not only larger in size,
more likely to be clinically signiﬁcant (42.9% versus 2.9%,
P = 0.001) but also more aggressive in terms of having
higher frequency of tumor bilaterality (45% versus 0%, P =
0.040) when compared to non-FDG-avid tumors [16, 17].
In fact, we advocated a total thyroidectomy even for FDG-
avid thyroid carcinoma <1cm in diameter because of the
high incidence of tumor bilaterality [16]. Therefore, our
data would support the fact that FDG-PET positivity implies
more aggressive tumor biology and poorer prognosis in
primary thyroid carcinoma.
4.PrognosticSigniﬁcance ofFDG-PET
PositivityinPersistentorRecurrent
Thyroid Carcinoma
Numerous studies have found that metastases from thyroid
carcinoma which do not concentrate RAI but take up FDG
are clinically more aggressive and have poorer tumor diﬀer-
entiation [7]. Esteva et al. studied 50 diﬀerentiated thyroid
carcinoma (DTC) patients with elevated thyroglobulin (Tg)
and negative whole-body scan (WBS) after total thyroidec-
tomy and RAI ablation. All patients underwent a FDG-PET
scan one week after the WBS [18]. The authors correlated
the postoperative FDG-PET ﬁnding and clinicopathological
variables of the primary tumor and found that FDG-PET
was positive in 32/39 patients with conﬁrmed persistent or
recurrent thyroid carcinoma. When compared to the FDG-
PET-negative group, the FDG-PET-positive group had sig-
niﬁcantly larger primary tumor size (2.82cm versus 1,72cm,
P<0.05) and these primary tumors were more likely to have
capsular invasion (62.5% versus 16.7%, P<0.05) suggesting
thatmore advancedprimary tumors were more likelytohave
FDG-PET-positive recurrences [18]. Rivera et al. studied
the histology of the metastases from 70 patients with RAI
refractory but FDG-PET-positive recurrences [19]. Of these
70patients,33(47.1%)hadpoorlyDTC,16(22.9%)hadwell
DTC, 6 (8.6%) had Hurthle cell carcinoma, and 1 (1.4%)
had anaplastic carcinoma. Based on these ﬁndings, the
majority ofRAIrefractory and FDG-PET positive metastases
are of a histological aggressive subtype. Interestingly, when
the histology of the primary tumor and its subsequent
metastases was matched, in most instances, there was a
gradual transformation from well-diﬀerentiated histology to
less-diﬀerentiated histology over time, and this might be the
reasonwhyeveniftheprimary tumormightnotbeFDGavid
initially,its metastases becomeFDGavidovertime[19].This
phenomenon was somewhat supported by a recent study
which found that BRAF mutations represented early events
in thyroid carcinogenesis, whereas mutations of PIK3CA and
AKT1 were latter events not found in the primary cancers,
but in metastases or recurrent cancers [20].
Apart from the direct relationship between FDG-PET
positivity and poorer histological diﬀerentiation in persis-
tent or recurrent thyroid carcinoma, it was observed that
patients with RAI-refractory but FDG-avid metastases were
signiﬁcantly more likely to die from thyroid carcinoma than
those with RAI-refractory and non-FDG-avid metastases.
This remained true when tumors were matched for TNM
stages. Using a Cox proportional hazard model, Robbins et
al. found that age (RR = 1.33; 95% CI: 1.08–1.52), FDG
status (RR = 7.69; 95% CI: 2.17–24.4), and number of FDG
lesions (RR = 1.1;95% CI: 1.08–1.15)signiﬁcantly correlated
with cancer-speciﬁc survivals [21]. Therefore, one could
conclude that FDG-PET positivity in persistent/recurrent
thyroid carcinoma and the number of FDGlesions are highly
prognostic for survival [21, 22].
5.Molecular Basis ofFDG-PET
PositivityinThyroidCarcinoma
Given the fact that mutations in signiﬁcant oncogenes such
as BRAF, TP53 (all of which are able to activate the mitogen-
activated proteinkinase pathway)are oftenpresentinaggres-
sivehistologicalsubtypes,itisreasonabletoassumethatboth
primary tumors and their metastases which are FDG-PET
positive would have a unique mutational proﬁle. Ricarte-
Filho et al. found that 100% of FDG-PET positive and
RAI refractory tumors carried BRAF mutations, whereas
in general only 45% of DTC would carry such mutations
[20]. This led to the postulation that perhaps there is a
causal relationship between BRAF mutations and FDG-PET
positivity. For the lack of RAI uptake in FDG-avid tumors,
it was shown for the ﬁrst time that in a DTC cell line, the
conditional activation of BRAFV600E tended to downregulate
the expression of the sodium iodide symporter (NIS) which
is an important ion pump for the transport of iodine across
basolateral membrane [23]. This ﬁnding was later conﬁrmed
in several studies showing that BRAFV600E was associated
with reduced NIS and NIS mRNA expression [24]. One of
the proposed mechanisms through which BRAF represses
NIS is by the inductionof robust transforming growthfactor
(TGF) β secretion and subsequent activation of TGFβ/Smad
signaling [25]. However, these ﬁndings would only explain
why these FDG-avid tumors do not take up RAI.To establish
the possible association between BRAF mutations and FDG-
PET positivity, Durante et al. examined the expression of
several key markers of thyrocyte diﬀerentiation including
NIS, Tg, thyroperoxidase, TSH receptor, transcription factor
PAX8, and glucose transporter type I (GLUT1) in 56
papillary thyroid carcinoma (PTC) with BRAF mutations
(i.e., BRAF-positive), 37 with no BRAF mutations (i.e.,
BRAF-negative),and8normalthyroidtissue[26].Relativeto
normal thyroid tissue, all markers including GLUT1 in PTCs
were reduced, but more importantly, there were additional
increases in GLUT1 mRNA when only the BRAF-positive
tumors were selected [26]. It is now believed that among the
four GLUT isoforms, GLUT1 is the most prevalent isoform
responsible for FDG-PET positivity in less-diﬀerentiated
thyroid carcinomas [27].4 Journal of Thyroid Research
Table 1:A comparisonofstudies examiningtheutility ofFDG-PET in detecting malignancyincytologically indeterminate thyroid nodules.
First author (year) No. of patients No. of carcinoma (%) Deﬁnition of FDG-PET positivity Sensitivity (%) Speciﬁcity (%)
Kresnik (2003) [28] 24 9 (37.5) Focal uptake with SUV > 2 100 100
Mitchell (2005) [29] 24 11 (45.8) Focal uptake 60 91
de Geus-Oei (2006) [30] 44 6 (13.6) Focal uptake 100 66
Sebastianes (2007) [31] 42 11 (26.2) Focal uptake 100 39
Hales (2008) [32] 15 7 (46.7) Focal uptake with SUV > 25 7 5 0
Smith (2008) [33] 23 5 (21.7) Area under SUV curve > 175.5 100 44
Traugott (2010) [34]5 1 ∗ 8 (15.6) Focal uptake 100 59
Vriens (2011) [35] 225# 58 (25.8) Varied 94.8 47.9
FDG-PET: ﬂuorodeoxyglucose positron emissiontomography; SUV: standardized uptake value.
∗An ongoing prospective trial; #a meta-analysis.
6.RoleofFDG-PET inthe Diagnosisof
Thyroid Carcinoma
Since histologically benign and malignant thyroid lesions do
exhibit some diﬀerences in SUV, FDG-PET may have an
important role in the characterization of thyroid nodules
and more speciﬁcally in the diagnosis of thyroid carcinoma.
However, currently the most cost-eﬀective and accurate
way of making the diagnosis of thyroid carcinoma relies
on clinical examination, the use of USG, and USG-guided
FNAC. Therefore, FDG-PET has not been widely accepted
as a diagnostic tool in thyroid carcinoma, but this may
change with time as technology improves[36].One aspect of
diagnosis in which FDG-PET scan has shown some promises
is in patients with an indeterminate thyroid lesion on FNAC.
By deﬁnition, an indeterminate FNAC usually includes
follicular lesions, Hurthle cell (oncocytic) lesions, atypical
cytology, abnormal cytology, or suspicious cytology. This
group remains a diagnostic dilemma to clinicians because
approximately 20–30% of these will be malignant, whereas
the rest will be benign by pathological examination [37,
38]. However, nearly all patients with indeterminate FNAC
would be required to undergo thyroid lobectomy to establish
the diagnosis. In other words, surgical resection will prove
unnecessary in over 60–70% of cases. At present, there is no
alternative algorithm for a more conservative management
for patients with indeterminate FNAC. Convectional USG,
computed tomography (CT), and magnetic resonance imag-
ing (MRI) have been previously shown to be of some value,
but FDG-PET is yet to be assessed in a large prospective
study [34]. Table 1 shows a comparison of series examining
the utility of FDG-PET in detecting malignancy in thyroid
nodule with indeterminate FNAC. Study size ranged from
15 to 51 patients, but the inclusion criteria varied between
studies. One of the larger series was reported by de Geus-Oei
et al. [30]. There were 44 patients with inconclusive FNAC
(i.e., follicular neoplasm, Hurthle cell neoplasm, atypical
cells, or inadequate) and of these, 6 were malignant and the
other 38 were benign. In their experience, FDG-PET did
not lead any false negatives implying a negative predictive
value (NPV) of 100%. All carcinomas demonstrated FDG
uptake, but 13 of 38 benign nodules also had FDG uptake.
They showed that using routine FDG-PET in their patient
cohort could potentially reduce the number of unnecessary
lobectomies by 66% (95% CI: 49–80%) if surgery was not
advised for those with no uptake in the thyroid gland on
FDG-PET imaging [30]. Importantly, no malignancies were
missed (i.e., no false negatives), but still there were 13/38
(34.2%) who underwent unnecessary lobectomies (i.e., false
positives). It was interesting to note in their series that
the mean SUV was similar between benign and malignant
lesions and one of the PTCs actually had SUV as low as 0.9.
To improve the false-positive rate, some studies proposed
using focal uptake SUV > 2.0 as the criterion for FDG-PET
positivity [28, 32]. However, for whatever cut-oﬀ in SUV,
there is always going to be a trade-oﬀ between false positives
and false negatives. Smith et al. evaluated the association
between SUV uptake over time and malignancy in follicular
neoplasm by performing serial FDG-PET scans over a 2-
hour period and measuring the area under the SUV curve
(AUC) [33]. They demonstrated no signiﬁcant diﬀerence
in AUC, but found a diﬀerence in the dynamics of SUV
changeovertimebetweenbenignandmalignantlesions[32].
Due to the signiﬁcant overlap in AUC, they concluded that
FDG-PET was not able to predict malignancy in a follicular
neoplasm [32]. However, since most of these reported series
were retrospective in design and the patient selection was
not formally standardized, there is a need for a large, well-
designed prospective study. Recently, Traugott et al. reported
the results of 51 patients with indeterminate FNAC as an
interimanalysisoftheirprospectivetrialwhichbeganin2004
[34]. Their data suggested that FDG-PET was an accurate
diagnostic modality for identifying malignancy in thyroid
nodules at least 1cm in diameter and with indeterminate
FNAC, with 100% sensitivity and NPV. They concluded
that FDG-PET was of value in excluding malignancy in
thyroid nodules with indeterminate FNAC. To overcome the
spatial resolution limitation of the FDG-PET, their study
only included solitary or dominant nodule that measured
≥1cm on USG. To achieve adequate power, they aimed to
recruit 125 patients and results would be available within
the next few years. A recent systematic review and meta-
analysis evaluated the role of FDG-PET in patients with
indeterminate thyroid FNAC [35]. In this meta-analysis,
they analyzed over 200 patients and found that the pooled
sensitivity, speciﬁcity, PPV, and NPV were 95%, 39%, 96%,Journal of Thyroid Research 5
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Figure 2: 18F-FDG-PET of a 73-year-old man with an 8-year history of papillary thyroid carcinoma.The serum thyroglobulin was elevated
at66ug/L (normal< 55ug/L),but bothdiagnosticwhole-body 131Iscanandultrasound were negative forrecurrence. (a)FDG-PET revealed
hypermetabolic uptakes in left cervical lymph node, right thyroid bed, and right sternoclavicular joint area. (b) An operative picture
conﬁrmingthe presence of tumor recurrence at the right thyroid bed (as pointed by the tip of the forceps).
and 60%, respectively. The authorsconcludedthat a negative
FDG-PETscaninpatientswhohadthyroidnodules>15mm
with indeterminate FNAB results excluded thyroid cancer
[35]. Conversely, a positive FDG-PET result did not identify
cancer because approximately 50% of these patients had
benign nodules [35]. They concluded that the incorporation
of FDG-PET into the initial workup of such patients before
surgery deserves further investigation [35]. However, there
are some concerns using FDG-PET in this group of patients.
Firstly, follicular thyroid carcinoma (FTC), which accounts
for 10–20% of malignancy in the indeterminate group,
is known to be associated with a lower SUV than other
histological types of thyroid carcinoma [39]. It is also known
that Hurthle cell adenoma, a benign lesion, tends to have
very high SUVs [28]. Both entities could possibly lessen
the usefulness of FDG-PET in discriminating benign from
malignant lesions in this indeterminate group. Furthermore,
a conﬁrmatory diagnosis in this group of FNAC is often
diﬃcult to make by experienced pathologists. It is known
that considerable interobserver and intraobserver variability
inthehistopathologicaldiagnosisofthyroidfollicularlesions
has been reported [40, 41]. In one recent study, among 15
cases of suspected follicular variant of PTC (FVPTC), only
2 cases (13.3%) had unanimous agreement among 6 expert
pathologists [41]. Given these concerns, the role of FDG-
PET in thyroid nodules with indeterminate FNAC remains
uncertain, but the interim results in one of the possibly
largest prospective trials on FDG-PET in cytologically inde-
terminate nodules looked promising [34]. Hopefully, this
prospective trial which is due to complete in the next few
years will provide us with more information.
7.RoleofFDG-PET inthe Managementof
Thyroid Carcinoma
Routine RAI diagnostic scanning or WBS for thyroid carci-
noma surveillance is becoming less frequently used because
of its relatively low sensitivity and has been supplanted by
serum Tg level and neck USG. Nowadays, one of the com-
monestclinicalscenarioswouldbeforapatientwithnegative
or normal USG but raised unstimulated Tg (i.e., >10ng/mL
or 10ug/L) [10]. FDG-PET is recommended in patients with
suspected recurrence or metastases in the setting of raised
Tg levels and scan-negative metastases (see Figures 2(a)
and 2(b))[ 10]. Earlier studies found that FDG-PET was a
useful diagnostic toolin thefollowupofpostsurgical patients
withDTC,negativeWBS,andabnormalTglevels[42].FDG-
PET was able to detect metastatic disease over 90% of cases
and more importantly, it was able to change the surgical tac-
tic in a 20–30% of cases [42]. Similarly, Wang et al. reported
their experience of 37 DTC patients with negative WBS and
elevated Tg, found that FDG-PET was able to locate occult
disease in 71%, and reported a positive predictive value
(PPV) of 92%. More importantly, FDG-PET was able to
change theclinicalmanagementinover50%ofpatients[43].
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of 93% [43]. Esteva et al. reported the FDG-PET ﬁndings
in 50 patients with elevated Tg and negative WBS and
found that FDG-PET was positive in 32/39 (82.1%) patients
with conﬁrmed recurrence and negative in 7/11 (63.6%)
with no conﬁrmed recurrence. The sensitivity and speciﬁcity
were 82% and 64%, respectively [18]. Tumor size and
capsular tumor invasion were factors signiﬁcantly associated
with a positive FDG-PET study [18]. They also concluded
that FDG-PET was an extremely useful imaging tool in
patients with negative WBS and raised Tg [18]. However, the
addedvalueofFDG-PET/CTovergood-qualityconventional
imaging modalities such as USG, CT, MRI, and diagnostic
WBS in locating recurrent or persistent DTC has recently
been questioned mainly of the extra cost with FDG-PET/CT
and the associated radiation. Lal et al. recently evaluated
the added value of FDG-PET/CT over conventional imaging
studies in 20 DTC patients with elevated Tg and negative
diagnostic WBS [44]. They found FDG-PET/CT provided6 Journal of Thyroid Research
Figure 3: 18F-FDG-PET/CT of a 57-year-old woman with a 10-year history of widely invasive follicular thyroid carcinoma. Serum thy-
roglobulin was elevated to 121ug/L (normal < 55ug/L), but both diagnostic whole-body 131I scan and ultrasound were negative. The FDG-
PET/CT revealed hypermetabolic FDG uptakes in the rib cage.
additional information in only 2/20 (10.0%) patients, both
of whom required no additional intervention, but under-
estimated the extent of disease in 3/30 (15.0%) patients
and led to unnecessary interventions (including surgery,
RAI, and antibiotics) in 3/30 (15.0%) additional patients.
They concluded that FDG-PET/CT has a good sensitivity
in detecting recurrent or persistent DTC, but the added
value over good-quality conventional imaging is very limited
[44]. Furthermore, it may lead to unnecessary interventions
[44]. Perhaps, future large prospective studies are required to
resolve some of the controversies.
Some studies evaluated the relationship between TSH
levelandFDGuptakeintensity[45–47].Todate,theevidence
seems to suggest that a higher SUVmax could be obtained
in TSH-stimulated condition by recombinant human TSH
(or rhTSH) stimulation, and as a result of high level of TSH,
greater number of FDG-avid metastases could be detected
on scanning [45–47]. Some authors evaluated the diagnostic
accuracy of integrated FDG-PET/CT as it was believed
that fusion of the two modalities may further enhance the
sensitivity, speciﬁcity, and tumor localization (see Figure 3).
For other types of head and neck tumors, combined FDG-
PET/CT has been shown to have improved diagnostic accu-
racy than FDG-PET or CT alone [48]. Razfar et al. evalu-
ated the diagnostic accuracy of integrity of FDG-PET/CT in
detecting recurrent/persistent DTC. They reported the sensi-
tivity, speciﬁcity, PPV, and NPV to be 80.7%, 88.9%, 94.7%,
and 65.3%, respectively. From their analysis, they demon-
strated there was an alteration in the treatment strategy in
28.2% as a result of adding the FDG-PET/CT information,
and 21% required additional surgery [49]. Therefore, it
would seem that FDG-PET/CT scan might be superior to
FDG-PETastheimagingofchoiceinpatientswithanegative
whole-body radioiodine scan and an abnormally raised
thyroglobulinlevelaftertotalthyroidectomyandradioiodine
ablation.
8.Conclusion
In patients with either primary or persistent/recurrent thy-
roid carcinoma, the ﬁnding of FDG-PET positivity or FDG-
avidity usually implies poorer tumor diﬀerentiation, more
aggressive tumor biology, and worse prognostic outcomes.
These observations are supported by the unique mutational
proﬁle of FDG-avid tumors or metastases, namely, increased
frequency of BRAF mutations leading to decreased NIS
and increased GLUT1. FDG-PET positivity may be a useful
potential risk factor for preoperative risk stratiﬁcation in
primary thyroid carcinoma and this information may help
in the planning of subsequent treatment strategy such asJournal of Thyroid Research 7
the extent of thyroidectomy, prophylactic central neck dis-
section, and RAI ablation. FDG-PET scan has the potential
in characterizing indeterminate thyroid nodules on FNAC.
However, larger-sized prospective studies are required to
validate this ﬁnding. FDG-PET or FDG-PET/CT scan has
become the imaging of choice in patients with a negative
WBS, but with an abnormally raised Tg level after total
thyroidectomy and RAI ablation.
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